Feverfew for preventing migraine

Wider, Barbara; Pittler, Max H; Ernst, Edzard

doi:10.1002/14651858.cd002286.pub3

Cited by 76 publications

(31 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the combination of feverfew, coenzyme Q10 and magnesium was well tolerated; only four adverse events of mild severity were reported in four patients. Feverfew, coenzyme Q10 and magnesium monopreparations have not been associated with major safety concerns in previous studies; only mild and transient adverse events, most commonly gastro-intestinal complaints were reported [ 5 , 7 , 20 ]. Now, tolerability and drug safety is a factor influencing compliance and maximization of compliance is one principle of preventive therapy [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…Despite the multitude of treatment options available, patients are often dissatisfied due to failure of achieving optimal control and cost of conventional drugs. In addition, some of the existing medications are associated with unacceptable adverse effects [ 5 ]. The need for effective treatments with less side effects explains, at least partly, the increasing interest toward non-pharmacologic alternatives for migraine prophylaxis, which include vitamins, minerals, and supplements along with herbal preparations.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study

Guilbot¹,

Bangratz²,

Abdellah³

et al. 2017

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundFeverfew (Tanacetum parthenium L.), magnesium and coenzyme Q10 are frequently used for migraine prophylaxis. Supplementation with a fixed combination of these three agents (Antemig®, PiLeJe) was investigated in an observational study.MethodsAdult patients suffering from migraine according to the criteria of the International Headache Society were enrolled by general practitioners (≥2 migraine attacks during previous month; exclusion of chronic migraine and medication overuse) and after a one-month baseline phase, supplemented with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months.ResultsSupplementation significantly reduced the number of days with migraine headache during third month of supplementation compared to baseline phase (1.3 days ±1.5 versus 4.9 days ±2.6, p < 0.0001; n = 68 intention to treat; primary criterion). The decrease was progressive over the period of supplementation and significant from first month (1st month: −2.5 days ±3.1, p < 0.0001; 2nd month: −3 days ±2.8, p < 0.0001). The proportion of patients with a reduction of at least 50% in the number of days with migraine headache was 75% (51/68) after 3 months, with a progressive increase over the period of supplementation (63.2% [43/68] after 1 month and 70.6% [48/68] after 2 months). The proportion of patients with anxiety and depressive symptoms (Hospital Anxiety and Depression Scale) decreased between baseline phase and third month of supplementation from 61.9% (39/63 patients with information available) to 35% (21/60) for depression and from 52.4% (33/63) to 30% (18/60) for anxiety. An improvement of quality of life (Qualité de Vie et Migraine questionnaire) was also observed. The combination was well tolerated.ConclusionsResults suggest that the proprietary supplement containing feverfew, coenzyme Q10 and magnesium assessed could be beneficial and safe for the prevention of migraine in adult patients and merits further study.Trial registrationClinicalTrials.gov: NCT02901756, retrospectively registered on August 24, 2016.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study

Guilbot¹,

Bangratz²,

Abdellah³

et al. 2017

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…Of note, no clear reduction in bone erosion was found and mechanical hypersensitivity was not investigated [18]. In a clinical trial in migraine sufferers, PAR was found to have no major safety concerns [20], although further studies are warranted.…”

Section: Introductionmentioning

confidence: 99%

Assessing the Effects of Parthenolide on Inflammation, Bone Loss, and Glial Cells within a Collagen Antibody-Induced Arthritis Mouse Model

Williams

Lees

Tsangari

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

Rheumatoid arthritis is characterised by a chronic inflammatory response resulting in destruction of the joint and significant pain. Although a range of treatments are available to control disease activity in RA, bone destruction and joint pain exist despite suppression of inflammation. This study is aimed at assessing the effects of parthenolide (PAR) on paw inflammation, bone destruction, and pain-like behaviour in a mild collagen antibody-induced arthritis (CAIA) mouse model. CAIA was induced in BALB/c mice and treated daily with 1 mg/kg or 4 mg/kg PAR. Clinical paw inflammation was scored daily, and mechanical hypersensitivity was assessed on alternate days. At end point, bone volume and swelling in the paws were assessed using micro-CT. Paw tissue sections were assessed for inflammation and pre-/osteoclast-like cells. The lumbar spinal cord and the periaqueductal grey (PAG) and rostral ventromedulla (RVM) regions of the brain were stained for glial fibrillary acidic protein (GFAP) and ionised calcium-binding adaptor molecule 1 (IBA1) to assess for glial reactivity. Paw scores increased in CAIA mice from days 5-10 and were reduced with 1 mg/kg and 4 mg/kg PAR on days 8-10. Osteoclast-like cells on the bone surface of the radiocarpal joint and within the soft tissue of the hind paw were significantly lower following PAR treatment (p<0.005). GFAP- and IBA1-positive cells in the PAG and RVM were significantly lower following treatment with 1 mg/kg (p<0.0001 and p=0.0004, respectively) and 4 mg/kg PAR (p<0.0001 and p=0.001, respectively). In the lumbar spinal cord, IBA1-positive cells were significantly lower in CAIA mice treated with 4 mg/kg PAR (p=0.001). The findings indicate a suppressive effect of both low- and moderate-dose PAR on paw inflammation, osteoclast presence, and glial cell reactivity in a mild CAIA mouse model.

show abstract

“…65 A systematic review of six low quality trials with 561 patients with migraine showed reduced headache frequency with a stable feverfew extract compared with baseline and with placebo (feverfew 4.8 baseline to 2.9 v placebo 4.8 to 3.5 headaches/month). 36 Feverfew was also studied as a homeopathic preparation in combination with ginger in an RCT of 60 patients with migraine with or without aura who had at least two but not more than 15 migraines a month. The combination, compared with placebo over 208 attacks treated at the onset of mild pain, resulted in greater pain reduction and pain relief at two hours (pain level feverfew-ginger 1.41 to 1.17 v control 1.67 to 1.70 (P<0.05); no pain feverfew-ginger 32.19% v control 15.79% (P<0.05)).…”

Section: Mind-bodymentioning

confidence: 99%

Complementary and integrative medicine in the management of headache

Millstine

Chen

Bauer

2017

BMJ

View full text Add to dashboard Cite

Headaches, including primary headaches such as migraine and tension-type headache, are a common clinical problem. Complementary and integrative medicine (CIM), formerly known as complementary and alternative medicine (CAM), uses evidence informed modalities to assist in the health and healing of patients. CIM commonly includes the use of nutrition, movement practices, manual therapy, traditional Chinese medicine, and mind-body strategies. This review summarizes the literature on the use of CIM for primary headache and is based on five meta-analyses, seven systematic reviews, and 34 randomized controlled trials (RCTs). The overall quality of the evidence for CIM in headache management is generally low and occasionally moderate. Available evidence suggests that traditional Chinese medicine including acupuncture, massage, yoga, biofeedback, and meditation have a positive effect on migraine and tension headaches. Spinal manipulation, chiropractic care, some supplements and botanicals, diet alteration, and hydrotherapy may also be beneficial in migraine headache. CIM has not been studied or it is not effective for cluster headache. Further research is needed to determine the most effective role for CIM in patients with headache.

show abstract

Feverfew for preventing migraine

Cited by 76 publications

References 52 publications

A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study

A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study

Assessing the Effects of Parthenolide on Inflammation, Bone Loss, and Glial Cells within a Collagen Antibody-Induced Arthritis Mouse Model

Complementary and integrative medicine in the management of headache

Contact Info

Product

Resources

About